



Informed Consent Assessment Form

STUDY PROTOCOL INFORMATION

Reference Number: ¹	
BulSU- ERC Code: ²	
Study Protocol Title:	
Principal Investigator:	<Title, Name, Surname>
Study Protocol Submission Date:	<dd/mm/yyyy>

INSTRUCTIONS

To the Principal Investigator:

Please indicate in the space provided below whether or not the specified element is addressed by the informed consent form (ICF). To facilitate the evaluation of the assessment point, indicate the page and paragraph where this information can be found.

To the Primary Reviewer:

Please evaluate how the elements outlined below have been appropriately addressed by the informed consent form (ICF), as applicable, and by confirming the submitted information and putting your comments in the space provided under "REVIEWER COMMENTS." In your comments, ensure that vulnerability, recruitment process, and process of obtaining informed consent are always assessed in the context of the study protocol and the participant. Finalize your review by indicating your conclusions under "RECOMMENDED ACTION" and signing in space provided for the primary reviewer.

Essential Elements (as applicable to the study)	To be filled out by the PI			REVIEWER COMMENTS
	Indicate if the ICF has the specified element	Page and paragraph where element is found		
	YES	N/A		
1. Statement that the study involves research				
2. Statement describing the purpose of the study				
3. Study-related treatments and probability for random assignment				
4. Study procedures including all invasive procedures				
5. Responsibilities of the participant				
6. Expected duration of participation in the study				
7. Approximate number of participants in the study				

¹ To be issued upon RMO registration

² To be issued upon initial processing by BULSU-ERC



8. Study aspects that are experimental				
9. Foreseeable risks to participant/embryo/ fetus/nursing infant; including pain, discomfort, or inconvenience associated with participation including risks to spouse or partner; and integrating risks as detailed in the investigator's brochure				
10. Risks from allowable use of placebo (as applicable)				
11. Reasonably expected benefits; or absence of direct benefit to participants, as applicable				
12. Expected benefits to the community or to society, or contributions to scientific knowledge				
13. Description of post-study access to the study product or intervention that have been proven safe and effective				
14. Alternative procedures or treatment available to participant				
15. Compensation or insurance or treatment entitlements of the participant in case of study-related injury				
16. Anticipated payment, if any, to the participant in the course of the study; whether money or other forms of material goods, and if so, the kind and amount				
17. Compensation (or no plans of compensation) for the participant or the participant's family or dependents in case of disability or death resulting from study-related injuries				
18. Anticipated expenses, if any, to the participant in the course of the study				
19. Statement that participation is voluntary, and that participant may withdraw anytime without penalty or loss of benefit to which the participant is entitled				
20. Statement that the study monitor(s), auditor(s), the UPMREB Ethics Review Panel, and regulatory authorities will be granted direct access to participant's medical records for purposes ONLY of verification of clinical trial procedures and data				
21. Statement that the records identifying the participant will be kept confidential and will not be made publicly				



available, to the extent permitted by law; and that the identity of the participant will remain confidential in the event the study results are published; including limitations to the investigator's ability to guarantee confidentiality				
22. Description of policy regarding the use of genetic tests and familial genetic information, and the precautions in place to prevent disclosure of results to immediate family relative or to others without consent of the participant				
23. Possible direct or secondary use of participant's medical records and biological specimens taken in the course of clinical care or in the course of this study				
24. Plans to destroy collected biological specimen at the end of the study; if not, details about storage (duration, type of storage facility, location, access information) and possible future use; affirming participant's right to refuse future use, refuse storage, or have the materials destroyed				
25. Plans to develop commercial products from biological specimens and whether the participant will receive monetary or other benefit from such development				
26. Statement that the participant or participant's legally acceptable representative will be informed in a timely manner if information becomes available that may be relevant to willingness of the participant to continue to participation				
27. Statement describing access of participant to the result of the study				
28. Statement describing extent of participant's right to access his/her records (or lack thereof <i>vis à vis</i> pending request for approval of non or partial disclosure)				
29. Foreseeable circumstances and reasons under which participation in the study may be terminated				
30. Sponsor, institutional affiliation of the investigators, and nature and sources of funds				
31. Statement whether the investigator is serving only as an investigator or as				



both investigator and the participant's healthcare provider				
32. Person(s) to contact in the study team for further information regarding the study and whom to contact in the event of study-related injury				
33. Statement that the BULSU-ERC Review Panel (specify) has approved the study, and may be reached through the following contact for information regarding rights of study participants, including grievances and complaints: Name of BulSU-ERC Panel Address: Email: Tel: Mobile:				
34. Comprehensibility of language used				
35. Other comments not addressed by items 1-34				
RECOMMENDED ACTION: • APPROVE • MINOR MODIFICATIONS • MAJOR MODIFICATIONS • DISAPPROVE • PENDING, IF MAJOR CLARIFICATIONS ARE REQUIRED BEFORE A DECISION CAN BE MADE				
JUSTIFICATION FOR RECOMMENDED ACTION				
PRIMARY REVIEWER Date: <dd/mm/yyyy>		Signature		
		Name	<Title, Name, Surname>	